A system for determining maximum tolerated dose in clinical trial (Q5880093): Difference between revisions

From MaRDI portal
Importer (talk | contribs)
Created a new Item
 
ReferenceBot (talk | contribs)
Changed an Item
 
(5 intermediate revisions by 4 users not shown)
Property / author
 
Property / author: Xiao-Bin Yang / rank
Normal rank
 
Property / author
 
Property / author: Xiao-Bin Yang / rank
 
Normal rank
Property / MaRDI profile type
 
Property / MaRDI profile type: MaRDI publication profile / rank
 
Normal rank
Property / full work available at URL
 
Property / full work available at URL: https://doi.org/10.1080/24754269.2021.1871708 / rank
 
Normal rank
Property / OpenAlex ID
 
Property / OpenAlex ID: W3121830851 / rank
 
Normal rank
Property / cites work
 
Property / cites work: Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial / rank
 
Normal rank
Property / cites work
 
Property / cites work: On the consistency of the continual reassessment method with multiple toxicity constraints / rank
 
Normal rank
Property / cites work
 
Property / cites work: Semiparametric Dose Finding Methods / rank
 
Normal rank
Property / cites work
 
Property / cites work: Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer / rank
 
Normal rank
Property / cites work
 
Property / cites work: Continual reassessment designs with early termination / rank
 
Normal rank
Property / cites work
 
Property / cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer / rank
 
Normal rank
Property / cites work
 
Property / cites work: Miscellanea. A stopping rule for the continual reassessment method / rank
 
Normal rank
Property / cites work
 
Property / cites work: Designs foe phase i cancer clinical trials with differentiation of graded toxicity / rank
 
Normal rank
Property / cites work
 
Property / cites work: A phase I dose-finding study based on polychotomous toxicity responses / rank
 
Normal rank
Property / cites work
 
Property / cites work: A study of the probit model with latent variables in Phase I clinical trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach / rank
 
Normal rank
Property / cites work
 
Property / cites work: Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design / rank
 
Normal rank
links / mardi / namelinks / mardi / name
 

Latest revision as of 15:05, 31 July 2024

scientific article; zbMATH DE number 7660278
Language Label Description Also known as
English
A system for determining maximum tolerated dose in clinical trial
scientific article; zbMATH DE number 7660278

    Statements

    A system for determining maximum tolerated dose in clinical trial (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    7 March 2023
    0 references
    Bayesian methods
    0 references
    continual reassessment method (CRM)
    0 references
    drug dose finding
    0 references
    Markov chain Monte Carlo (MCMC) method
    0 references
    maximum tolerated dose (MTD)
    0 references
    phase I clinical trial
    0 references
    toxicity responses
    0 references

    Identifiers